Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

Key Takeaways VRTX fell 8.9% over three months due to soft Q1 results and slower uptake of new and CF drugs. Alyftrek, Journavx, and Casgevy sales are expected to pick up in the second half of 2025. VRTX's CF franchise remains strong, with 2025 sales projected to grow 8% amid pipeline expansion.Vertex Pharmaceuticals Incorporated (VRTX) stock has declined 8.9% in the past three months.The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as well as CF drug ...